Subscribe to magazine
Subscribe to newsletters
Roundtable: Stereotactic Breast Imaging
Technology Report: Artificial Intelligence (NEW)
Technology Report: CT
Technology Report: Digital Radiography
Technology Report: Enterprise Imaging (NEW)
Technology Report: MRI
Technology Report: Radiation Therapy
Whitepaper: Interoperability Challenge and Solutions
Themed Blogs: Greg Freiherr
Computed Tomography (CT)
Digital Radiography (DR)
Magnetic Resonance Imaging (MRI)
Radiation dose management
Radiographic Fluoroscopy (RF)
Breast Biopsy Systems
Ultrasound Women's Health
Clinical decision support
Flat panel displays
Imaging software development
Remote viewing systems
Vendor neutral archives (VNA)
Treatment planning software/systems
Oncology information management systems (OIMS)
Baylor Scott White Hospital
Henry Ford Hospital
Navidea Biopharmaceuticals Inc.
425 Metro Place North, Suite 450
Dublin, OH 43017
October 16, 2014
FDA Approves Expanded Use of Navidea’s Lymphoseek for Lymphatic Mapping in Solid Tumors
Navidea Biopharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the...
September 29, 2014
Lymphoseek Recommended for European Approval in Sentinel Lymph Node Detection
Navidea Biopharmaceuticals, Inc. has announced that that the Committee for Medicinal Products for Human Use of the...
June 17, 2014
Lymphoseek Demonstrates Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes
June 17, 2014 — Navidea Biopharmaceuticals Inc. announced results from a post-hoc analysis of patient data from the...
June 13, 2014
FDA Approves Lymphoseek to Help Determine Extent of Head and Neck Cancer
June 13, 2014 — The U.S. Food and Drug Administration (FDA) today approved a new use for Navidea Biopharmaceuticals’...
April 16, 2014
Navidea Provides Update on European Marketing Authorization Application for Lymphoseek
Navidea Biopharmaceuticals Inc. held an update meeting with the Committee for Medicinal Products for Human Use (CHMP)...
March 07, 2014
Navidea Announces Acceptance for Review of an Additional sNDA to Further Expand Lymphoseek Labeling
Navidea Biopharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review an...
February 28, 2014
Priority Review Given to Expand Lymphoseek Labeling for Sentinel Lymph Node Detection
Navidea Biopharmaceuticals Inc. is a biopharmaceutical company focused on precision diagnostic ...
September 03, 2013
Navidea Biopharmaceuticals Signs Manufacturing Agreement with Siemens’ PETNET Solutions for Beta-Amyloid Imaging Agent
September 3, 2013 — Navidea Biopharmaceuticals Inc., a biopharmaceutical company focused on precision diagnostic...
May 08, 2013
Navidea Begins U.S. Launch of Lymphoseek Tc-99 Tracer
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of...
April 29, 2013
Results of NAV4694 Amyloid Imaging Agent Clinical Trial Published
Navidea Biopharmaceuticals Inc. announced the peer-reviewed publication of results from a clinical trial of NAV4694 in...
Scranton Gillette Communications
. All Rights Reserved.
Topics We Cover
Terms and Conditions